SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of molecular
diagnostic assays, products and services designed to provide
physicians with clinically actionable information to improve
patient outcomes, announces that it has been awarded Hong Kong
Patent No. 1188285 entitled, METHODS AND REAGENTS FOR SIGNAL
AMPLIFICATION. This patent covers methods for enhancing the
detection of cells using fluorescent complexes, including
circulating tumor cells (CTCs).
The method covered by this patent expands Biocept's patent
protection for sensitive detection of cancer cells. This technology
combines seamlessly with Biocept's core technologies using
antibodies for CTC enrichment, as well as Biocept's microchannel
intellectual property for the capture, enrichment, and imaging of
CTCs from patients with cancer collected in Biocept's patented
blood transport tube. This could also be important in future
applications such as with Single Cell Analysis.
"This patent extends our coverage for capturing and analyzing
rare cells of interest, including CTCs, and expands our
international footprint, which is a strategic priority as we
work to grow our business globally," said Michael Nall, Biocept's President and CEO. "This
patent brings our total intellection property portfolio covering
our molecular diagnostic technologies to 44."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, melanoma, and tumors metastatic to the central
nervous system (brain and spinal cord). The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. In addition,
Biocept is conducting COVID-19 testing to support efforts to fight
the pandemic. For additional information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve patient
outcomes, and the ability of our tests to provide clinically
actionable information to oncologist and their patients, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-receives-hong-kong-patent-covering-the-enhanced-detection-of-rare-cells-including-cancer-cells-301167780.html
SOURCE Biocept, Inc.